Pharmacogenetic Aspects of Therapy with Cholinesterase Inhibitors: The Role of CYP2D6 in Alzheimer's Disease Pharmacogenetics

Publisher： Bentham Science Publishers

E-ISSN： 1875-5828|4|4|479-500

ISSN： 1567-2050

Source： Current Alzheimer Research, Vol.4, Iss.4, 2007-09, pp. : 479-500

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Sex and Gender Differences in the Brain Cholinergic System and in the Response to Therapy of Alzheimer Disease with Cholinesterase Inhibitors

By  

Current Alzheimer Research, Vol. 15, Iss. 11, 2018-09 ,pp. : 1077-1084

Bentham Science Publishers

Access to resources Recommend Favorite

Cholinesterase inhibitors in Alzheimer's disease: a consensus view on managing treatment failure

By Emre Murat   Farlow Martin   Bullock Roger   Gauthier Serge   Grossberg George   Potkin Steven G  

Primary Care Psychiatry, Vol. 9, Iss. 1, 2004-01 ,pp. : 29-30

Informa Healthcare

Access to resources Recommend Favorite

Cholinesterase inhibitors in Alzheimer’’s disease: sooner or later or both?

By Kerwin Robert  

Future Neurology, Vol. 1, Iss. 6, 2006-11 ,pp. : 737-740

Future Medicine

Access to resources Recommend Favorite

"Value for money" in treating Alzheimer's disease with the new cholinesterase inhibitors

By Shah Ajit   Jenkins Rachel  

International Journal of Psychiatry in Clinical Practice, Vol. 7, Iss. 1, 2003-01 ,pp. : 45-47

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: Update and report from a pharmacogenetic service clinic

By Müller Daniel J.   Kekin Ivana   Kao Amy C. C.   Brandl Eva J.  

International Review of Psychiatry, Vol. 25, Iss. 5, 2013-10 ,pp. : 554-571

Informa Healthcare

Access to resources Recommend Favorite